Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754047 | 0.80 | EPHX1 (0.41) | HPGDEPHX1L3MBTL1KDM4EPKM | |
| SCHEMBL9963459 | 0.78 | EPHX1 (0.40) | HPGDEPHX1L3MBTL1KDM4EPKM | |
| SCHEMBL24702231 | 0.78 | POLB (0.41) | EPHX1KDM4EKMT2AALDH1A1PIK3CD | |
| SCHEMBL18658966 | 0.78 | POLB (0.41) | EPHX1KDM4EKMT2AALDH1A1PIK3CD | |
| SCHEMBL19392024 | 0.77 | EPHX1 (0.39) | HPGDEPHX1L3MBTL1KDM4EPKM | |
| SCHEMBL9966002 | 0.77 | EPHX1 (0.39) | HPGDEPHX1L3MBTL1KDM4EPKM | |
| SCHEMBL23964744 | 0.77 | EPHX1 (0.39) | HPGDEPHX1L3MBTL1KDM4EPKM | |
| SCHEMBL27722586 | 0.74 | POLB (0.30) | — | |
| SCHEMBL25762057 | 0.73 | EPHX1 (0.37) | HPGDEPHX1L3MBTL1KDM4EPKM | |
| SCHEMBL25869801 | 0.71 | POLB (0.41) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300074-B2 | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300074-B2 | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy | BIRC3, API5, XIAP | HPGD 2940/4885EPHX1 4316/4885L3MBTL1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.